Litcius/Paper detail

Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice

Yuka Hayakawa, Kaoru Tsuchiya, Masayuki Kurosaki, Yutaka Yasui, Shun Kaneko, Yuki Tanaka, Shun Ishido, Kento Inada, Sakura Kirino, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Ryuichi Okamoto, Namiki Izumi

2021Investigational New Drugs56 citationsDOI

Topics & Concepts

AtezolizumabBevacizumabMedicineResponse Evaluation Criteria in Solid TumorsInternal medicineOncologyHepatocellular carcinomaProgressive diseaseCancerChemotherapyPembrolizumabImmunotherapyHepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentHER2/EGFR in Cancer Research
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice | Litcius